Mobile immunotherapy with chimeric antigen receptor (CAR)-T cells (CARTs) represents a breakthrough within the therapy of hematologic malignancies. CARTs are genetically engineered hybrid receptors that
Group A Streptococcus (GAS) is a preeminent human bacterial pathogen inflicting a whole bunch of hundreds of thousands of infections every year worldwide. Within the medical setting,